Approximately 200 people from around the world attended OMERACT 9 May 27-31 in Kananaskis, Canada. Developed in 1992, OMERACT stands for Outcome Measures in Rheumatology. Originally limited to outcome measures in rheumatoid arthritis clinical trials, the initiative has since evolved to include outcome measurement across the spectrum of rheumatology intervention studies. While fibromyalgia is not a rheumatic disease, the disorder currently falls under this diagnostic “umbrella.”
“OMERACT plays a significant role in facilitating improved outcome measurements in intervention studies, which ultimately benefit patients,” says Phillip Mease, M.D., who chairs or co-chairs three working groups of OMERACT: fibromyalgia, psoriatic arthritis, and single joint assessment.
According to Lynne Matallana, president and founder of the National Fibromyalgia Association and a member of the OMERACT fibromyalgia working committee, the level of interest in and understanding of fibromyalgia has increased significantly since the committee’s prior meeting in 2006 in Malta. This year’s program included a module dedicated solely to fibromyalgia.
The fibromyalgia community was well represented at the meeting, with OMERACT and the National Fibromyalgia Association collaborating to obtain funding for fibromyalgia patients to attend. Matallana was joined by three other individuals who suffer from fibromyalgia: Sharon Waldrop of Michigan, Michael Peterman of Florida, and Kathryn Longley of the United Kingdom. Each of these individuals spoke at the meeting, participated in the patient workshops and was granted voting rights.
These patient representatives played a crucial role by sharing the patient perspective and guiding several discussions, leading the group to decisions that will be implemented in future fibromyalgia research.
Participants also included dozens of physicians and researchers worldwide, as well as James Witter, MD, the chief science officer for the National Institutes of Health’s PROMIS (Patient-Reported Outcomes Measurement Information System) program. Witter spoke on the impact that PROMIS will have on patient-doctor communications, earlier diagnosis and improved treatment.
For more information on OMERACT, click here.
This article was originally published in FMOnline. This free online newsletter is only available to registered members.
Click here to register! View other articles in Vol. 8, No. 6 newsletter:
In the Spotlight
Taking Control of MCS
Multiple Chemical Sensitivities
Amputated Lives: Coping with Chemical Sensitivity
Top Tips for Dealing with Multiple Sensitivities
MCS-Friendly Product Ideas
Management Tips for People with Chemical Sensitivities
Book Review: The Lonely Patient
In the News
California Assembly Passes Resolution for the First-Ever Fibromyalgia Task Force
Veterans Pain Care Act of 2008
Canadian FM Attitudes
The State of Women’s Health Research
Author Seeks Interview Subjects
Looking for Faces of FAME
World Focus on FM
NFA Exhibits at EULAR
Jazzed After A Day of Volunteering
Artículos en Español
Vivir con Sensibilidad Química Múltiple
Sensibilidad Química Múltiple